Pardes Biosciences to Present at Cowen Healthcare Conference

Rhea-AI Summary

Pardes Biosciences, Inc. (NASDAQ: PRDS) announced that CEO Thomas G. Wiggans and Chief Scientific Advisor Uri A. Lopatin will present a company overview at the 42nd Annual Cowen Healthcare Conference on March 9, 2022, at 11:10 a.m. PT. This event takes place virtually from March 7-9, 2022. Pardes is developing PBI-0451, a novel oral antiviral for SARS-CoV-2 infections, including COVID-19. A live audio webcast of the presentation will be available on Pardes' website, with an archived replay accessible for 30 days.

CARLSBAD, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), announced that Thomas G. Wiggans, Chief Executive Officer, and Uri A. Lopatin, M.D., Chief Scientific & Strategic Advisor, will present a company overview at the 42^nd Annual Cowen Healthcare Conference on Wednesday, March 9, 2022 at 11:10 a.m. PT / 2:10 p.m. ET. The conference will take place virtually from March 7-9, 2022.

A live audio webcast of the presentation will be available in the Investors section of Pardes’ website at www.pardesbio.com, with an archived replay available for 30 days following the event.

About Pardes Biosciences, Inc. 

Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates. For more information, please visit www.pardesbio.com.

Availability of Other Information about Pardes Biosciences

Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure). Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes’ press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

Investor Contact:
ir@pardesbio.com

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

FAQ

When will Pardes Biosciences present at the Cowen Healthcare Conference?

Pardes Biosciences will present on March 9, 2022, at 11:10 a.m. PT.

What is the focus of Pardes Biosciences' presentation?

The presentation will cover the company's development of PBI-0451, an oral antiviral drug for COVID-19.

Where can I watch the Pardes Biosciences presentation?

The presentation can be viewed on Pardes' website during a live audio webcast.

What is PBI-0451 developed by Pardes Biosciences?

PBI-0451 is a potential unboosted oral antiviral drug candidate for treating SARS-CoV-2 infections.

How long will the presentation replay be available?

The archived replay of the presentation will be available for 30 days after the event.